Navigation Links
InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System
Date:12/7/2010

BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the publication of a case report in Circulation describing the association of stent thrombosis with lipid core plaque as detected by its LipiScan™ Coronary Imaging System. The LipiScan is the first and only FDA-approved system to provide a Chemogram™ (map of lipid core plaque) within the imaged vessel via near-infrared (NIR) spectroscopy. The authors note that the case represents the first demonstration of acute stent thrombosis associated with disrupted lipid core plaque (LCP) as detected by NIR imaging with the LipiScan system.

The paper titled "Residual Thrombogenic Substrate After Rupture of a Lipid Rich Plaque – Possible Mechanism of Acute Stent Thrombosis? A Near-Infrared Spectroscopy Study" was published in Circulation (2010;122:2349-2350) under authors Sakhuja R., Suh W., Jaffer F. and Jang I.

"While stenting is an excellent means to treat flow restrictions caused by coronary plaques, it is in some cases complicated by thrombosis which may cause serious consequences," said James E. Muller, M.D., founder and chief executive officer of InfraReDx. "This report by Sakhuja et al. describes the occurrence of thrombosis in a stent that ends in a lipid core plaque, a structure that contains substances known to be thrombogenic. This adds to the accumulating evidence that many complications of stenting – peri-stenting infarction, stent thrombosis and restenosis – are due not to features of the stent or stenting technique, but to the presence of a lipid core plaque at the stented site. We are pleased to make available the LipiScan IVUS Coronary Imaging System, which provides an easy and accurate method to detect lipid core plaque and thereby adds important information to the decision-making process."

Since this LipiScan examination was performed, InfraReDx has received FDA clearance (see September 1, 2010 news release) for its next-generation LipiScan IVUS Coronary Imaging System, which now combines both NIR (LipiScan) and intravascular ultrasound (IVUS) technologies. The IVUS feature provides an image of the plaque and coronary artery lumen, while the NIR feature provides rapid and accurate assessment of LCPs. Upon completion of a single catheter pullback, the LipiScan IVUS system is able to immediately generate and display a grayscale IVUS image of the coronary artery, along with a complete and co-registered Chemogram within the imaged vessel.

About InfraReDx, Inc.InfraReDx, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraReDx's LipiScan™ IVUS Coronary Imaging System is the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to both visualize and characterize the intracoronary lipid core plaques (LCP) suspected of causing the majority of heart attacks. Founded in 1998, InfraReDx is headquartered in Burlington, Massachusetts. For more information, visit www.infraredx.com.  Contacts:Susan Heins (media)Pure Communications, Inc.864-286-9597sjheins@purecommunicationsinc.com Grant FrazierVice President of MarketingInfraReDx, Inc.781-345-9632gfrazier@infraredx.com
'/>"/>

SOURCE InfraReDx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
3. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
4. InfraReDxs LipiScan(TM) Coronary Imaging System for Identification of Lipid Core Plaque to be Highlighted at 59th Annual Scientific Session of the American College of Cardiology
5. InfraReDxs New LipiScan™ IVUS Coronary Imaging System to be Highlighted at TCT 2010
6. InfraReDx Completes $21 Million Equity Financing
7. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
8. InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... July 11, 2017  Bayer has awarded grants totaling more ... part of its prestigious Bayer Hemophilia Awards Program (BHAP). Four ... Philadelphia and Uniformed Services University of the ... the winners. Grant recipients were announced last night during a ... 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
Breaking Medicine Technology:
(Date:7/21/2017)... ORLEANS, La. (PRWEB) , ... July 21, 2017 ... ... to allow 4th-year medical students improve their chances of acceptance to a residency ... for those who have earned degrees outside the U.S. , According to data ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital ... adjustable beds used in such facilities are specially designed to accommodate patients with a ... , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, ...
(Date:7/20/2017)... MD (PRWEB) , ... July 20, 2017 , ... ... company dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary ... million. , Proceeds will be used to complete regulatory submissions and fund final ...
Breaking Medicine News(10 mins):